Skip to main content

Table 8 Comparison between combined inhalants and non-inhalants use groups with control group regarding WCST domains

From: Cognitive dysfunction in adolescents with substance use disorder

 

Combined inhalants use group

Non-inhalant use group

Control group

p-Value

N = 100

N = 40

N

Mean ± SD

N

Mean ± SD

N

Mean ± SD

Number of categories completed

21

1 ± 1

79

3 ± 1

40

5 ± 1

0.034*

Trials to first category

21

37 ± 4

79

31 ± 3

40

20 ± 3

0.01**

Failure to maintain set

21

3 ± 1

79

1 ± 1

40

1 ± 1

0.03*

Total number of errors

21

76 ± 8

79

56 ± 13

40

34 ± 4

0.05*

Number of perseverative errors

21

41 ± 3

79

30 ± 8

40

18 ± 3

0.01**

Number of perseverative responses

21

49 ± 4

79

43 ± 4

40

26 ± 4

0.04*

Number of non-perseverative errors

21

35 ± 5

79

26 ± 7

40

16 ± 5

0.07

  1. *p-value < 0.05 significance. **p-value < 0.01 significance. Shows that combined inhalant use group shows lower mean than control group, non-inhalant use group as regard number of category completed, and the difference had statistically critical p = 0.034. Combined inhalant use group shows higher mean than control, non-inhalants use groups as regard trial to first category, failure to maintain set, total number of errors, number of perseverative errors, and number of perseverative responses; the difference had statistically critical p = 0.05, which mean that inhalants use impairs early conceptualization, sustained attention, and flexibility domains. Combined inhalant use group shows higher mean than control, non-inhalants use groups as regard number of non-perseverative errors, but the difference had not statistically critical